In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective.We covered 4 important practice informing studies with Dr. Liu:- FLAURA2 – studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets- CHRYSALIS-2 – post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination with Lazertinib plus chemo- MARS2 – when compared surgery followed by chemo vs chemo alone, chemo alone had better outcomes in patients with resectable mesothelioma- EVOKE-02 – Sacituzumab approved bladder and breast cancer, was tested here along with Pembrolizumab in 1st line mNSCLC setting, with more data to come to confirm its arrival in this space#WCLC #IASLC #LungCancer #2023 #cancer #oncology #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: https://twitter.com/oncbrothersContact us at info@oncbrothers.com
chemo
In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective.We covered 4 important practice informing studies with Dr. Liu:- FLAURA2 – studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets- CHRYSALIS-2 – post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination with Lazertinib plus chemo- MARS2 – when compared surgery followed by chemo vs chemo alone, chemo alone had better outcomes in patients with resectable mesothelioma- EVOKE-02 – Sacituzumab approved bladder and breast cancer, was tested here along with Pembrolizumab in 1st line mNSCLC setting, with more data to come to confirm its arrival in this space#WCLC #IASLC #LungCancer #2023 #cancer #oncology #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: https://twitter.com/oncbrothersContact us at info@oncbrothers.com
In discussion with Dr. Stephen Liu, covering the World Conference on Lung Cancer Highlights from Community Oncology perspective.We covered 4 important practice informing studies with Dr. Liu:- FLAURA2 – studying the importance of Osimertinib + chemo vs. Osimertinib in EGFRm patients, PFS benefit in the combination arm, though pending OS and most benefit derived in patients with CNS mets- CHRYSALIS-2 – post progression on EGFR therapy, there is ORR benefit from adding Amivantamab in combination with Lazertinib plus chemo- MARS2 – when compared surgery followed by chemo vs chemo alone, chemo alone had better outcomes in patients with resectable mesothelioma- EVOKE-02 – Sacituzumab approved bladder and breast cancer, was tested here along with Pembrolizumab in 1st line mNSCLC setting, with more data to come to confirm its arrival in this space#WCLC #IASLC #LungCancer #2023 #cancer #oncology #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: https://twitter.com/oncbrothersContact us at info@oncbrothers.com
In discussion with Dr. Jeff Sharman, about how to treat CLL. Chronic lymphocytic leukemia course has changed since we have started using BTK inhibitors. Dr. Sharman, director of hematology research at US Oncology Network and Director of Research at Willamette Valley Cancer Institute, was the first to ever give this medication here in the US. We discuss important nuances of CLL management with him, when to proceed with observation vs. treatment, when treating what BTKi to utilize, important side effects one has to keep in mind, and much more.#treatment #algorithm #CLL #venetoclax #2023 #cancer #oncology #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: https://twitter.com/oncbrothersContact us at info@oncbrothers.com
Going from competing in beauty pageants and going to college, to being diagnosed with cancer. A northern Kentucky college student is in the fight of her life. But instead of giving up or being angry, she’s determined to win, just like she always has. Anna Ferris has been competing in beauty pageants since she was 9 years old. She’s 20 now and still loves the feeling of being up there on that stage and taking home the crown. The plan was to compete this summer and hopefully get to the state competition, but life took a cruel turn. “I had a cough that lingered around for about four months. At first, I thought it was just a cold. As soon as my pediatrician said we saw the scan and you have a mass in your chest, I burst into tears. And I’m not a crier at all usually and I kind of didn’t want to believe it,” Ferris said.It was a gut punch to Anna’s mom, Wendy, too. “I went into fight mode. I couldn’t be the one breaking down in front of her because I needed to be strong. So we’re just going to power through this and get her back to her normal self,” Wendy Ferris said. Anna was diagnosed with Hodgkin’s lymphoma. She immediately had to start an aggressive round of chemotherapy. Suddenly, everything, from pageants, sorority life and even college, is on hold. Anna has no idea when she’ll be able to go back. Chemo treatments can be a dark, quiet, lonely place. Anna’s mom said this is not the way things were supposed to go. “Especially when you know Anna and she is the sweetest, kindest person. So to see her in pain or hurting is definitely hard. But she definitely shines through it. She’s just that way,” Wendy Ferris said. Somehow, Anna still has that sparkle, just like her crown. But no one, not even her mom, expected what Anna would do in the middle of this brutal fight.Anna says with a smile, “I kind of had gotten over the fact that I had no hair and I was just like, why not send it and see what happens? And the worst that can happen has already happened. I mean, I already have cancer, so what else can happen?” Not only did Anna compete, she won!She’s Alexandria Fairgrounds Kentucky’s reining Miss Alexandria Fair and, suddenly, an inspiration to every person who sees her. She was crowned at the Alexandria Fair & Horse Show.Anna’s message now is to “be nice to everyone because you never know what they’re going through. Although some might be obvious because they might be bald.” Anna has a long battle ahead: more chemo, then radiation, but she’s already planning for the state competition in January. There’s no stopping this beauty queen. “My name is Anna Ferris and I am Ms. Alexandria Fair 2023. And I am strong,” Anna said.”My daughter is Anna Ferris and she is a fighter. And she is blessed,” Wendy said. Despite all of this, Anna is still taking online classes at Western Kentucky. Anna has always wanted to be a pediatrician. She says this cancer battle has made her want to help kids even more.
Iâm sorry I havenât made a video in awhile. This whole entire year has been so overwhelming! Some of you know I took care of my Mother who had dementia for about 3 years. She passed away back on April 5th. đ˘ My oldest brother passed away back on July 20th after a 2 year battle with angiosarcoma. One week later, my now husband was diagnosed with stage 4 pancreatic cancer. đđđ I canât make this stuff up yâall. đ I wasnât able to go to my brothers visitation or funeral because my husband had to have surgery and he needed me. Of course everyone understood, but I still havenât grieved his loss. This is a short video I made bc we just got married back on September 3rd after being together for almost 23 yeats. đ First marriage for us both! I just turned 48 and he is 54. Itâs so strange saying âmy husbandâ. đ I never in my life imagined we would end up married, but Iâm so happy we did it! đâ¤ď¸
Bone marrow transplant donations save lives but for patients of color, finding a match is incredibly challenging.
Bone marrow transplant donations save lives but for patients of color, finding a match is incredibly challenging.
Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin’s Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg – Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).#immunotherapy #oncology #fda #polatuzumab #nivolumab #2023 #cancer #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin’s Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg – Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).#immunotherapy #oncology #fda #polatuzumab #nivolumab #2023 #cancer #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: / oncbrothers Contact us at info@oncbrothers.com
#bloodcancer #cancersurvivor #cancerawareness In this video, I share how I was diagnosed with Multiple Myeloma. Multiple Myeloma is a blood cancer. In this video, I talk about my initial multiple myeloma symptoms and how it took a year to finally get my diagnosis. I also share the various treatments I have had throughout my journey. I talk about what chemotherapy I was given and how I ended up getting Car-T cell therapy. I am not a medical professional but just offering a patient perspective on navigating cancer. If you feel something off with your body please consult with a healthcare professional.People oftentimes ask if I take supplements to help give my health a boost and I do. Here are a few links to my favorite supplement brands. Vitamin D https://amzn.to/3qTFyrbCurcumin https://amzn.to/3R5XJobResveratrol https://amzn.to/3PwG6NjDisclaimer: The above links are affiliate links and by clicking on them I may receive a small commission.
Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin’s Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg – Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).#immunotherapy #oncology #fda #polatuzumab #nivolumab #2023 #cancer #oncbrothersWebsite: http://www.oncbrothers.com/Twitter: / oncbrothers Contact us at info@oncbrothers.com